Extensive genomic profiling research has established that basal-subclassified BLCA exhibits two distinct therapy advantages, namely, maximized intratumoral lymphocyte infiltration and superior objective response rates to PD-1 inhibitor therapies, including pembrolizumab (47). The gene discussed is PDCD1; the disease is bladder transitional cell carcinoma.